LAMP1 and neoplasm: In vitro studies showed anti-NKG2A Monalizumab treatment prompts increased CD107a expression, a marker for activated NK cells, and IFN-γ production by IL-2 activated NK cells and CD8+ T cells, yielding significant improvements in tumor growth control and prognosis (104).